Immunogen (IMGN)

ImmunoGen Stock Analysis & Ratings

IMGN Stock Chart & Stats

Day’s Range$3.85 - $3.96
52-Week Range$3.46 - $7.77
Previous Close$3.82
Average Volume (3M)3.52M
Market Cap$866.71M
P/E Ratio-6.3
Next EarningsJul 29, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score6
EPS (TTM)-0.60



P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.


Risk Analysis

Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was ImmunoGen’s price range in the past 12 months?
ImmunoGen lowest stock price was $3.46 and its highest was $7.77 in the past 12 months.
    What is ImmunoGen’s market cap?
    ImmunoGen’s market cap is $866.71M.
      What is ImmunoGen’s price target?
      The average price target for ImmunoGen is $10.00. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $18.00 ,the lowest forecast is $4.00. The average price target represents 154.45% Increase from the current price of $3.93.
        What do analysts say about ImmunoGen?
        ImmunoGen’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 6 Wall Streets Analysts.
          When is ImmunoGen’s upcoming earnings report date?
          ImmunoGen’s upcoming earnings report date is Jul 29, 2022 which is in 73 days.
            How were ImmunoGen’s earnings last quarter?
            ImmunoGen released its earnings results on May 06, 2022. The company reported -$0.1 earnings per share for the quarter, beating the consensus estimate of -$0.211 by $0.111.
              Is ImmunoGen overvalued?
              According to Wall Street analysts ImmunoGen’s price is currently Undervalued.
                Does ImmunoGen pay dividends?
                ImmunoGen does not currently pay dividends.
                What is ImmunoGen’s EPS estimate?
                ImmunoGen’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does ImmunoGen have?
                ImmunoGen has 220,540,000 shares outstanding.
                  What happened to ImmunoGen’s price movement after its last earnings report?
                  ImmunoGen reported an EPS of -$0.1 in its last earnings report, beating expectations of -$0.211. Following the earnings report the stock price went down -4.536%.
                    Which hedge fund is a major shareholder of ImmunoGen?
                    Among the largest hedge funds holding ImmunoGen’s share is RA Capital Management. It holds ImmunoGen’s shares valued at 103M.


                      ImmunoGen Stock Analysis

                      The ImmunoGen stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description


                      ImmunoGen, Inc. is a biotechnology company, which engages in discovering and developing antibody-drug conjugate therapies that meaningfully improve the lives of people with cancer. Its product candidates include Mirvetuximab soravtansine, Coltuximab ravtansine, IMGN7779 and IMGN632. The company was founded in March 1981 and is headquartered in Waltham, MA.

                      Similar Stocks
                      Price & Change
                      CytomX Therapeutics
                      Roche Holding
                      Eli Lilly & Co

                      Popular Stocks

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis